Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Heather ValerioMaryam AlaviDavid SilkCarla TreloarMarianne MartinelloAndrew MilatAdrian DunlopJo HoldenCharles HendersonJanaki AminPhillip ReadPhilippa MarksLouisa DegenhardtJeremy HayllarDavid ReidCarla GortonThao LamGregory J DoreJason Grebely

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

Unrestricted direct-acting antiviral therapy access in Australia has yielded high treatment uptake among PWID attending drug treatment and NSPs, with a marked decline in HCV prevalence. To achieve elimination, PWID with greater marginalization may require additional support and tailored strategies to enhance treatment.

Keyphrases

emergency department
hepatitis c virus
stem cells
risk factors
bone marrow
antiretroviral therapy
adverse drug